olfactory receptor family 52 subfamily N member 5Genealiases: OR11-62 · OR52N5Q
Q-omics provides the consensus-scored OR52N5 profile across patient tissues and cancer cell-line models. OR52N5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, OR52N5 is differentially expressed in 3, with the highest sampling consensus in PAAD. Additionally, OR52N5 RNA expression shows 6,912 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, PAAD, and TGCT as cancer lineages where OR52N5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52N5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52N5 survival associations across molecular data types. OR52N5 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52N5 RNA expression–survival associations across cancer types. High OR52N5 expression shows unfavorable associations in UCS, KICH, COAD, KIRP, CESC and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for OR52N5 RNA expression.
This table summarizes OR52N5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR52N5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52N5 shows lower tumor expression in PAAD and LUSC and higher tumor expression in LIHC. The PAAD box plot shows higher OR52N5 RNA expression in normal versus tumor tissue (log2 FC = −0.095, t-test p = .002).
This table shows molecular features associated with OR52N5 in patient tissues and cancer cell lines. In patient samples, OR52N5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OR52N5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
